Project Grant R01DK143456
- This $161,664 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop "DREAM: BUILDING EQUITABLE PREDICTIVE MODELS FOR PERSONALIZED DIABETES PHARMACOTHERAPY." The project has three key objectives: (1) creating predictive models to estimate individualized outcomes like HbA1c, weight, and hypoglycemia for diabetes medication options,...
- This $1,021,719.00 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Emmyon, Inc., is developing a novel small molecule therapeutic (EMMY1-25) that has demonstrated the ability to promote weight loss without muscle loss and protect against dysfunction of pancreatic beta cells in mouse models of obesity and type 2...
- This Project Grant award, valued at $747,133.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research by the Monell Chemical Senses Center to behaviorally, physiologically, anatomically, and molecularly characterize a population of neurons in the nucleus tractus solitarius (NTS) that express glucagon-like peptide-1 receptors (GLP1R) and...
- The federal Project Grant award, "GLUCOSE PATTERNS AND CLINICAL OUTCOMES IN THE DALLAS HEART STUDY: A PATHWAY TO PRECISION DIABETES - CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEMS", is provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $819,091 award to The Johns Hopkins University will fund research to use CGM and machine learning methods to identify...
- This $804,342 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research at Duke University to investigate the metabolic actions of glucagon, a hormone that plays a key role in glucose regulation. Specifically, the research aims to characterize how glucagon receptor signaling in the liver engages divergent pathways that...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $410,000.00 to The University of Texas Southwestern Medical Center to study the effects of glucagon-like peptide 1 (GLP-1) receptor agonists and brain-derived GLP-1 on the activity of neuropeptide Y/agouti-related peptide (NPY/AGRP) neurons and their impact on metabolism. The research aims to define the...
- This Project Grant award of $714,440 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports a research study to advance precision diabetes medicine. The key objectives are to: Define subphenotypes of prediabetes and early type 2 diabetes based on underlying metabolic physiology, including insulin resistance, beta-cell function, incretin effect, and hepatic insulin resistance. Evaluate...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $3,145,056 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Duke University. The project aims to collect real-world evidence on the use of anti-obesity medications (AOMs) in adolescents, examining the reach, effectiveness, and potential unintended consequences of these treatments within clinical settings. The 4-year project will recruit a cohort of...
- This federal Project Grant award in the amount of $1,428,186.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Massachusetts. The project aims to investigate the role of CYP4F enzymes in regulating N-acyl amino acid signaling in humans, which has implications for understanding the early...
- This federal Project Grant award of $803,748 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant is funding research to investigate the modulation of insulin signaling in adipocytes (fat cells) and how improved adipocyte insulin sensitivity can contribute to positive metabolic outcomes. The research team at The University of Texas Southwestern Medical...
This $802,363 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will fund a research study at Emory University from September 2025 to June 2030 to develop models for predicting the benefits of GLP-1 receptor agonist (GLP-1RA) treatments in preventing obesity-related cardiometabolic diseases. The study aims to use clinical and genetic data to inform precision health policy design for GLP-1RA coverage. Key objectives include developing an agent-based microsimulation model for obesity-related cardiometabolic complications and predictive models for the magnitude of GLP-1RA treatment response in preventing these complications. The integrated models will be used to conduct large-scale simulation experiments and develop a scoring system to guide precision health policy for GLP-1RA coverage.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $802.4k | 9/18/25 |